Adipocytokines and hepatic fibrosis

Trends in Endocrinology and Metabolism

Volumn 26, Issue 3, 2015, Pages 153-161

  Saxena, Neeraj K ^a   Anania, Frank A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipocytokines; Adiponectin; Hepatic stellate cells; Leptin; Liver fibrosis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APELIN; INTEGRIN; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL BINDING PROTEIN 4; VASPIN;

ADIPOCYTE; CHRONIC LIVER DISEASE; ENDOCRINE FUNCTION; FOCAL ADHESION; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; MOLECULAR BIOLOGY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; FATTY LIVER; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADIPOKINES; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; METABOLIC SYNDROME X;

EID: 84923567807     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.01.002     Document Type: Review

References (92)

1. Duval F., et al. Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells. Adv. Pharmacol. Sci. 2014, 2014:373295.
2. Lade A., et al. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr. Opin. Oncol. 2014, 26:100-107.
3. Yin C., et al. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Invest. 2013, 123:1902-1910.
4. Novo E., et al. Cellular and molecular mechanisms in liver fibrogenesis. Arch. Biochem. Biophys. 2014, 548:20-37.
5. Iwaisako K., et al. Strategies to detect hepatic myofibroblasts in liver cirrhosis of different etiologies. Curr. Pathobiol. Rep. 2014, 2:209-215.
6. Xu J., et al. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front. Pharmacol. 2014, 5:167.
7. Wells R.G. The portal fibroblast: not just a poor man's stellate cell. Gastroenterology 2014, 147:41-47.
8. Mallat A., et al. Autophagy: a multifaceted partner in liver fibrosis. Biomed. Res. Int. 2014, 2014:869390.
9. Puche J.E., et al. Hepatic stellate cells and liver fibrosis. Compr. Physiol. 2013, 3:1473-1492.
10. Meli R., et al. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front. Immunol. 2014, 5:177.
11. Mallat A., Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am. J. Physiol. Cell Physiol. 2013, 305:C789-C799.
12. Schuppan D., Kim Y.O. Evolving therapies for liver fibrosis. J. Clin. Invest. 2013, 123:1887-1901.
13. DePaoli A.M. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J. Endocrinol. 2014, 223:T71-T81.
14. Giby V.G., Ajith T.A. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J. Hepatol. 2014, 6:570-579.
15. Polyzos S.A., et al. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 2015, 64:60-78.
16. Nseir W., et al. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig. Dis. Sci. 2011, 56:3439-3449.
17. Zezos P., Renner E.L. Liver transplantation and non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20:15532-15538.
18. Duan X.F., et al. Obesity, adipokines and hepatocellular carcinoma. Int. J. Cancer 2013, 133:1776-1783.
19. Marra F., et al. Modulation of liver fibrosis by adipokines. Dig. Dis. 2011, 29:371-376.
20. Bertolani C., Marra F. Role of adipocytokines in hepatic fibrosis. Curr. Pharm. Des. 2010, 16:1929-1940.
21. Procaccini C., et al. Leptin: the prototypic adipocytokine and its role in NAFLD. Curr. Pharm. Des. 2010, 16:1902-1912.
22. Ferris W.F., Crowther N.J. Once fat was fat and that was that: our changing perspectives on adipose tissue. Cardiovasc. J. Afr. 2011, 22:147-154.
23. Paz-Filho G., et al. Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arq. Bras. Endocrinol. Metabol. 2010, 54:690-697.
24. Polyzos S.A., Mantzoros C.S. Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism 2015, 64:5-12.
25. Munzberg H., Morrison C.D. Structure, production and signaling of leptin. Metabolism 2015, 64:13-23.
26. Zhou Q., et al. GATA binding protein 2 mediates leptin inhibition of PPARgamma1 expression in hepatic stellate cells and contributes to hepatic stellate cell activation. Biochim. Biophys. Acta 2014, 1842:2367-2377.
27. Choi S.S., et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J. Biol. Chem. 2010, 285:36551-36560.
28. Cortes V.A., et al. Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. J. Lipid Res. 2014, 55:276-288.
29. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Prac. Res. Clin. Gastroenterol. 2011, 25:195-206.
30. Wallace M.C., Friedman S.L. Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. Gene Expr. 2014, 16:77-84.
31. Handy J.A., et al. Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem. J. 2011, 440:385-395.
32. Hernandez-Gea V., Friedman S.L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 2011, 6:425-456.
33. Chung H.K., et al. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation. Liver Int. 2014, Published online December 1, 2014. http://dx.doi.org/10.1111/liv.12741.
34. Trak-Smayra V., et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int. J. Exp. Pathol. 2011, 92:413-421.
35. Yang Y.Y., et al. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis. Clin. Sci. 2012, 123:669-680.
36. Yang Y.Y., et al. Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats. Hepatology 2012, 55:1540-1550.
37. Zhou Q., et al. GATA binding protein 2 mediates leptin inhibition of PPARgamma1 expression in hepatic stellate cells and contributes to hepatic stellate cell activation. Biochim. Ebiophys. Acta 2014, 1842:2367-2377.
38. Zhou Y., et al. PI-3K/AKT and ERK signaling pathways mediate leptin-induced inhibition of PPARgamma gene expression in primary rat hepatic stellate cells. Mol. Cell. Biochem. 2009, 325:131-139.
39. Kukla M., et al. Potential role of leptin, adiponectin and three novel adipokines, visfatin, chemerin and vaspin, in chronic hepatitis. Mol. Med. 2011, 17:1397-1410.
40. Seki E., Schwabe R.F. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 2014, Published online July 26, 2014. http://dx.doi.org/10.1002/hep.27332.
41. Yan K., et al. p38 mitogen-activated protein kinase and liver X receptor-alpha mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol. Med. 2012, 18:10-18.
42. Zhai X., et al. The beta-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis. Br. J. Pharmacol. 2013, 169:197-212.
43. Zhao L., et al. Adiponectin and insulin cross talk: the microvascular connection. Trends Cardiovasc Med. 2014, 24:319-324.
44. Moschen A.R., et al. Adiponectin: key player in the adipose tissue-liver crosstalk. Curr. Med. Chem. 2012, 19:5467-5473.
45. Buechler C., et al. Adiponectin, a key adipokine in obesity related liver diseases. World J. Gastroenterol. 2011, 17:2801-2811.
46. Koppe S.W. Obesity and the liver: nonalcoholic fatty liver disease. Transl. Res. 2014, 164:312-322.
47. Briggs D.B., et al. Role of redox environment on the oligomerization of higher molecular weight adiponectin. BMC Biochem. 2011, 12:24.
48. Misu H., et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS ONE 2012, 7:e34952.
49. Vrachnis N., et al. Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. Int. J. Endocrinol. 2012, 2012:549748.
50. Kumar P., et al. Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS ONE 2014, 9:e110405.
51. Cao T., et al. AdipoR1/APPL1 potentiates the protective effects of globular adiponectin on angiotensin II-induced cardiac hypertrophy and fibrosis in neonatal rat atrial myocytes and fibroblasts. PLoS ONE 2014, 9:e103793.
52. Ahsan M.K., Mehal W.Z. Activation of adenosine receptor A2A increases HSC proliferation and inhibits death and senescence by down-regulation of p53 and Rb. Front. Pharmacol. 2014, 5:69.
53. Kumar P., et al. Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis. FASEB J. 2014, 28:5172-5183.
54. Janmey P.A., et al. From tissue mechanics to transcription factors. Differentiation 2013, 86:112-120.
55. Lee Y.A., et al. The role of adiponectin in the production of IL-6, IL-8, VEGF and MMPs in human endothelial cells and osteoblasts: implications for arthritic joints. Exp. Mol. Med. 2014, 46:e72.
56. Okada-Iwabu M., et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503:493-499.
57. Pepping J.K., et al. Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by hiv protease inhibitors. J. Neuroimmune Pharmacol. 2014, 9:388-398.
58. Otvos L., et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 2011, 11:90.
59. Granzow M., et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014, 60:334-348.
60. Tan M., et al. Adiponectin attenuates Ang-induced TGFbeta1 production in human mesangial cells via an AMPK-dependent pathway. Biotechnol. Appl. Biochem. 2014, Published online December 4, 2014. http://dx.doi.org/10.1002/bab.1323.
61. Qi G.M., et al. Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology 2014, 155:2254-2265.
62. Fang F., et al. The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res. Ther. 2012, 14:R229.
63. Beier J.I., Arteel G.E. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp. Biol. Med. 2012, 237:1-9.
64. Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. J. Cell. Physiol. 2012, 227:493-507.
65. Samarakoon R., et al. TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell. Signal. 2013, 25:264-268.
66. Chanda D., et al. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology 2009, 50:880-892.
67. Baeck C., et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 2014, 59:1060-1072.
68. Miura K., et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G1310-G1321.
69. Marra F., Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014, 147:577-594.
70. Cantley J. The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. Mamm. Genome 2014, 25:442-454.
71. Xia M., et al. Retinol binding protein 4 stimulates hepatic sterol regulatory element-binding protein 1 and increases lipogenesis through the peroxisome proliferator-activated receptor-gamma coactivator 1beta-dependent pathway. Hepatology 2013, 58:564-575.
72. Li Y., et al. Adipokines and hepatic insulin resistance. J. Diabetes Res. 2013, 2013:170532.
73. Al-Suhaimi E.A., Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur. J. Med. Res. 2013, 18:12.
74. Nobili V., et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012, 56:2142-2153.
75. Dong Z.X., et al. Resistin mediates the hepatic stellate cell phenotype. World J. Gastroenterol. 2013, 19:4475-4485.
76. Shen C., et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol. 2014, 14:39.
77. Castan-Laurell I., et al. Apelin, diabetes, and obesity. Endocrine 2011, 40:1-9.
78. Krist J., et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes. Facts 2013, 6:57-69.
79. Principe A., et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008, 48:1193-1201.
80. Fukuhara A., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
81. Nan Y.M., et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis. 2013, 12:11.
82. Yang R., et al. High glucose induces Rho/ROCK-dependent visfatin and type I procollagen expression in rat primary cardiac fibroblasts. Mol. Med. Rep. 2014, 10:1992-1998.
83. Bozaoglu K., et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148:4687-4694.
84. Docke S., et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur. J. Endocrinol. 2013, 169:547-557.
85. Heiker J.T. Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. J. Pept. Sci. 2014, 20:299-306.
86. Byrne C.D., Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1155-1161.
87. Lanthier N., et al. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:404-411.
88. Dranoff J.A., Wells R.G. Portal fibroblasts: underappreciated mediators of biliary fibrosis. Hepatology 2010, 51:1438-1444.
89. Brenner D.A., et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 2012, 5(Suppl 1.):S17.
90. Iwaisako K., et al. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J. Gastroenterol. Hepatol. 2012, 27(Suppl. 2):65-68.
91. Seki E., Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J. Physiol. 2012, 590:447-458.
92. Iwakiri Y., et al. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J. Hepatol. 2014, 61:912-924.